Jazz Pharmaceuticals PLC (JAZZ)

159.85
3.71 2.38
NASDAQ : Health Care
Prev Close 156.14
Open 156.88
Day Low/High 155.63 / 160.57
52 Wk Low/High 108.50 / 194.73
Volume 460.49K
Avg Volume 442.70K
Exchange NASDAQ
Shares Outstanding 60.09M
Market Cap 9.37B
EPS 6.60
P/E Ratio 23.05
Div & Yield N.A. (N.A)

Latest News

Jazz Pharmaceuticals Announces Positive Results From The Phase 3 TONES 2 Study Of JZP-110 In Narcolepsy Patients With Excessive Sleepiness

Abstract Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017

Jazz Pharmaceuticals Announces Positive Results From The Phase 2/3 EXPRESS Study Of Xyrem In Pediatric Patients With Narcolepsy With Cataplexy

Abstract Accepted for Oral Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Jazz Pharmaceuticals Reaches Settlement With Hikma Pharmaceuticals Related To Xyrem Patent Litigation

Hikma Granted Right to Sell Authorized Generic of Xyrem in 2023

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, CAA, JAZZ, LFL, MTH, SUM, WYNN Downgrades: REV, TROW, WAGE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Jazz Pharmaceuticals Announces Positive Results From The Phase 3 TONES 3 And TONES 4 Studies Of JZP-110 In Patients With Obstructive Sleep Apnea

Abstracts Accepted for Presentation at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) in June 2017

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.

How Investors Can Play the Trump Card: Cramer's 'Mad Money' Recap (Monday 1/23/17)

How Investors Can Play the Trump Card: Cramer's 'Mad Money' Recap (Monday 1/23/17)

Jim Cramer looks for domestic stocks he thinks will benefit from lower taxes and deregulation in the Trump era.

Fitbit Is Out, Xilinx Is In: 'Mad Money' Lightning Round

Fitbit Is Out, Xilinx Is In: 'Mad Money' Lightning Round

Jim Cramer says the future doesn't look healthy for Fitbit, but he's bullish on Xilinx and T-Mobile.

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

CoLucid Pharmaceuticals saw shares boost 32% ahead of the market open Wednesday.

The Best Biopharma CEOs of 2016 Are...

The Best Biopharma CEOs of 2016 Are...

The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CSWC, FNV, INTT, SCHL, VSAT Downgrades: AE, ASH, CNTY, CVV, HCOM, JAZZ, JLL, KND, MAC, MGNX, NS, OLED, OLP, SCSC, SEAS, TGH, XNCR Initiations: ABTX Read on to get TheStreet Quant Ratings' detailed report:

Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short

Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short

Jazz Pharmaceuticals's third-quarter results missed analysts' projections.

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

Jazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance

Jazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance

Jazz Pharmaceuticals (JAZZ) reported lower earnings and revenue for the 2016 second quarter and gave an outlook below Wall Street's expectations.

3 Health Care Stocks Pushing The Sector Higher

3 Health Care Stocks Pushing The Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Jazz Pharma (JAZZ) Stock Receives ‘Outperform’ Rating at BMO Capital

Jazz Pharma (JAZZ) Stock Receives ‘Outperform’ Rating at BMO Capital

Jazz Pharma (JAZZ) stock coverage was started with an ‘outperform’ rating and $190 price target at BMO Capital.

Stocks Climb Slightly in May Despite Fed Fears

Stocks Climb Slightly in May Despite Fed Fears

U.S. markets ended May on a positive note, despite fears over the likelihood of a summer rate hike by the Federal Reserve that made trading unpredictable.